Breaking News Instant updates and real-time market news.

NVST

Envista

$28.53 /

+0.29 (+1.03%)

09:09
12/17/19
12/17
09:09
12/17/19
09:09

Envista resumed with an Outperform at Evercore ISI

Evercore ISI analyst Elizabeth Anderson resumed coverage of Envista (NVST) with an Outperform rating and $35 price target following the recently-concluded share exchange related to Danaher (DHR) splitting off its remaining interest in Envista. Danaher's divestiture of its remaining stake has removed an overhang and the company is starting to reap the benefits of prior work to accelerate core revenue growth and expand margins, Anderson tells investors.

NVST Envista
$28.53 /

+0.29 (+1.03%)

10/14/19 MSCO
Envista initiated with an Equal Weight at Morgan Stanley
10/14/19 EVER
Envista initiated with an Outperform at Evercore ISI
10/14/19 WBLR
Envista initiated with an Outperform at William Blair
10/14/19
Fly Intel: Top five analyst initiations

TODAY'S FREE FLY STORIES

Hot Stocks
First Bancshares raises quarterly dividend to 10c from 8c per share » 20:54
01/21/20
01/21
20:54
01/21/20
20:54
FBMS

First Bancshares

$33.70 /

-0.4 (-1.17%)

The dividend is payable…

The dividend is payable on February 21, 2020 to shareholders of record as of the close of business on February 7, 2020.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
First Bancshares reports Q4 EPS 72c, consensus 74c » 20:54
01/21/20
01/21
20:54
01/21/20
20:54
FBMS

First Bancshares

$33.70 /

-0.4 (-1.17%)

Reports Q4 NII $33.8M vs.…

Reports Q4 NII $33.8M vs. $25.5M last year. Reports Q4 net interest margin 4.06% vs. 4.08% last year.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Syndicate
NanoViricides 2.5M share Secondary priced at $3.00 » 20:39
01/21/20
01/21
20:39
01/21/20
20:39
NNVC

NanoViricides

$8.10 /

+4.76 (+142.51%)

Aegis is acting as sole…

Aegis is acting as sole book running manager for the offering.

Earnings
Notable companies reporting before tomorrow's open » 20:25
01/21/20
01/21
20:25
01/21/20
20:25
ABT

Abbott

$89.76 /

+0.76 (+0.85%)

, BKR

Baker Hughes

$22.72 /

-0.9 (-3.81%)

, ALLY

Ally Financial

$30.25 /

-0.19 (-0.62%)

Notable companies…

Notable companies reporting before tomorrow's open, with earnings consensus, include Abbott (ABT), consensus 95c... Baker Hughes (BKR), consensus 31c... Ally Financial (ALLY), consensus 93c.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Medtronic price target raised to $135 from $125 at Piper Sandler » 20:03
01/21/20
01/21
20:03
01/21/20
20:03
MDT

Medtronic

$120.30 /

+1.32 (+1.11%)

Piper Sandler analyst…

Piper Sandler analyst Matt O'Brien raised his price target on Medtronic to $135 and kept his Overweight rating after its announcement that the FDA has approved its Micra AV pacemaker. The analyst sees the approval as an "opportunity to materially increase" Micra's total addressable market, adding that Medtronic clearly possesses the superior technology in the pacemaker space and currently has a leg up against the competition.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
WellCare, Centene satisfy merger requirements » 19:49
01/21/20
01/21
19:49
01/21/20
19:49
CNC

Centene

$65.48 /

+0.96 (+1.49%)

, WCG

WellCare

$340.52 /

+3.55 (+1.05%)

Centene (CNC) and…

Centene (CNC) and WellCare (WCG) announced that they now have satisfied all regulatory requirements under the merger agreement to complete the pending transaction, including review by the U.S. Department of Justice. Subject to the satisfaction of customary closing conditions, the parties expect to close the transaction and the related divestitures of WellCare's Medicaid and Medicare Advantage plans in Missouri, WellCare's Medicaid plan in Nebraska and Centene's Medicaid and Medicare Advantage plans in Illinois on or about January 23, 2020.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
Apple suppliers to start making new low-cost iPhone in February, Bloomberg says » 19:17
01/21/20
01/21
19:17
01/21/20
19:17
AAPL

Apple

$316.39 /

-2.27 (-0.71%)

, HNHPF

Hon Hai Precision

$0.00 /

+ (+0.00%)

Apple (AAPL) suppliers…

Apple (AAPL) suppliers intend to start assembling a new low-cost iPhone in February as the tech giant looks to address a wider share of the global smartphone market ahead of its 5G handsets later this year, Bloomberg's Debby Wu and Mark Gurman report, citing people familiar with the plan. The company is expected to officially reveal the new phone as early as March, the authors say, citing one person familiar with the road map. The assembly work for the new phone will be split among Hon Hai Precision (HNHPF), Pegatron, and Wistron, the authors note. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Syndicate
Ellington Financial 4.6M share Spot Secondary priced at $18.29 » 19:12
01/21/20
01/21
19:12
01/21/20
19:12
EFC

Ellington Financial

$18.85 /

+0.13 (+0.69%)

Morgan Stanley, Credit…

Morgan Stanley, Credit Suisse, BofA, UBS and Keefe Bruyette are acting as joint book running managers for the offering.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22
    Jan
Downgrade
Minerva SA downgraded to Sell from Neutral at Goldman Sachs » 18:59
01/21/20
01/21
18:59
01/21/20
18:59
MRVSY

Minerva SA

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Goldman Sachs analyst Luca Cipiccia downgraded Minerva SA to Sell from Neutral with a R$19 price target. The analyst contends that the backdrop for LatAm beef exports should remain favorable, but the recent spike in cattle prices in Brazil may reduce domestic demand.

Downgrade
Grupo Lala downgraded to Sell from Neutral at Goldman Sachs » 18:57
01/21/20
01/21
18:57
01/21/20
18:57
GRPBF

Grupo Lala

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Goldman Sachs analyst Luca Cipiccia downgraded Grupo Lala to Sell from Neutral with a MXN 35.80 price target. The analyst is concerned that the company's slowdown in growth that started in the first half of 2019 will continue and margins will remain under pressure amid deteriorating margin conditions and waning impact from efficiency initiatives.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Compania Cervecerias downgraded to Neutral from Buy at Goldman Sachs » 18:53
01/21/20
01/21
18:53
01/21/20
18:53
CCU

Compania Cervecerias

$19.00 /

-0.33 (-1.71%)

Goldman Sachs analyst…

Goldman Sachs analyst Luca Cipiccia downgraded Compania Cervecerias to Neutral from Buy. The analyst is citing limited short term catalysts and potential downside risk to estimates due to a fragile consumer environment and FX headwinds in Chile and Argentina.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Grupo Lala upgraded to Buy from Neutral at Goldman Sachs » 18:50
01/21/20
01/21
18:50
01/21/20
18:50
GRPBF

Grupo Lala

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Goldman Sachs analyst Luca Cipiccia upgraded Grupo Lala to Buy from Neutral with a MXN 25 price target. The analyst sees the stock valued attractively following the sell-off related to the company CEO departure and also believes that company may be an M&A target for larger multi-national players.

Upgrade
Gruma upgraded to Buy from Neutral at Goldman Sachs » 18:48
01/21/20
01/21
18:48
01/21/20
18:48
GPAGF

Gruma

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Goldman Sachs analyst Luca Cipiccia upgraded Gruma to Buy from Neutral with a MXN 243 price target. The analyst cites the company's "defensive" Mexican exposure in corn flour, expected top-line re-acceleration in the U.S., and its attractive valuation.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Coca-Cola Femsa upgraded to Buy from Neutral at Goldman Sachs » 18:47
01/21/20
01/21
18:47
01/21/20
18:47
KOF

Coca-Cola Femsa

$62.52 /

+0.41 (+0.66%)

Goldman Sachs analyst…

Goldman Sachs analyst Luca Cipiccia upgraded Coca-Cola Femsa to Buy from Neutral with a MXN 149 price target. The analyst cites the company's stronger contribution from Brazil and a very attractive valuation.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Logitech CEO: We're growing all three of our businesses at a healthy clip » 18:46
01/21/20
01/21
18:46
01/21/20
18:46
LOGI

Logitech

$47.77 /

+1.2 (+2.58%)

In an interview on…

In an interview on CNBC's Mad Money, Logitech CEO Bracken Darrell said, "We delivered strong gross margins despite the tariff impacts. We're growing all three of our businesses at a healthy clip." Darrell noted that the Video Collaboration business is a "huge opportunity" and there is a "big opportunity in the home - it is the future for us."

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Fly Intel: After Hours Movers » 18:44
01/21/20
01/21
18:44
01/21/20
18:44
NAVI

Navient

$13.86 /

-0.01 (-0.07%)

, IBM

IBM

$139.15 /

+0.84 (+0.61%)

, COF

Capital One

$102.29 /

-1.85 (-1.78%)

, FBK

FB Financial

$38.20 /

-0.66 (-1.70%)

, NFLX

Netflix

$338.24 /

-1.32 (-0.39%)

, MNLO

Menlo Therapeutics

$6.48 /

-0.17 (-2.56%)

, CIT

CIT Group

$45.23 /

-1.17 (-2.52%)

, SKT

Tanger Factory

$15.93 /

+0.56 (+3.64%)

, ETN

Eaton

$94.51 /

-1.19 (-1.24%)

, SUPN

Supernus

$24.70 /

+0.26 (+1.06%)

, ZION

Zions Bancorp

$49.93 /

-0.81 (-1.60%)

, IBKR

Interactive Brokers

$50.89 /

+0.7 (+1.39%)

, AMTD

TD Ameritrade

$50.76 /

+0.25 (+0.49%)

, FULT

Fulton Financial

$17.26 /

-0.07 (-0.40%)

, UAL

United Airlines

$85.84 /

-3.84 (-4.28%)

, ADAP

Adaptimmune

$4.14 /

-0.38 (-8.41%)

, BPMC

Blueprint Medicines

$79.69 /

-1.46 (-1.80%)

, ELAN

Elanco

$30.64 /

+0.65 (+2.17%)

UP AFTER EARNINGS:…

UP AFTER EARNINGS: Navient (NAVI) up 5.9%... IBM (IBM) up 3.8%... Capital One (COF) up 2.2%... FB Financial (FBK) up 2.0%... Netflix (NFLX) up 2.0%... ALSO HIGHER: Menlo Therapeutics (MNLO) up 7.4% after disclosing passive stake by Point72... CIT Group (CIT) up 5.8% after entering S&P MidCap 400 index... Tanger Factory (SKT) up 3.6% after entering S&P SmallCap 600 index... Eaton (ETN) up 2.0% after selling Hydraulics business for $3.3B... Supernus Pharma (SUPN) up 1.3% after FDA accepted SPN-812 NDA for review. DOWN AFTER EARNINGS: Zions Banc (ZION) down 1.7%... Interactive Brokers (IBKR) down 1.6%... TD Ameritrade (AMTD) down 1.5%... Fulton Financial (FULT) down 1.5%... United Airlines (UAL) down 0.2%... ALSO LOWER: Adaptimmune Therapeutics (ADAP) down 5.8% after equity offering... Blueprint Medicines (BPMC) down 5.3% after equity offering... Elanco (ELAN) down 2.3% after equity offering... Movers as of 18:30ET.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22
    Jan
  • 23
    Jan
  • 23
    Jan
Hot Stocks
Supernus: FDA accepts for review NDA for SPN-812 » 18:35
01/21/20
01/21
18:35
01/21/20
18:35
SUPN

Supernus

$24.70 /

+0.26 (+1.06%)

Supernus announced that…

Supernus announced that the U.S. FDA has found the New Drug Application for SPN-812 for the treatment of children and adolescents with attention deficit hyperactivity disorder acceptable for review. The FDA has assigned a Prescription Drug User Fee Act target action date of November 8, 2020.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Netflix says doesn't want to 'exploit' users with advertising » 18:31
01/21/20
01/21
18:31
01/21/20
18:31
NFLX

Netflix

$338.24 /

-1.32 (-0.39%)

Says mobile-only plans in…

Says mobile-only plans in Asia have added subscribers. Says wants to experiment with and test out yearly subscription plans. Says not integrating everybody's data. Says confident that best business model in the long-term is current model, as opposed to ad-based model. Says want to be a "safer" site where users can enjoy content. Says doesn't want to "exploit" users with advertising.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Costco CEO: We're a volume company, not a margin company » 18:25
01/21/20
01/21
18:25
01/21/20
18:25
COST

Costco

$313.28 /

+8.6 (+2.82%)

In an interview on…

In an interview on CNBC's Mad Money, Costco CEO Craig Jelinek said, "We always want to pay great wages. Our average wage is about $25 per hour. We think we're a great place to work and we want long-term employees." Jelinek noted that, "We're a volume company, not a margin company. We do a lot with very few units." He said the company will continue to expand, but "will not have a store on every corner." When discussing capital allocation, Jelinek said, "we have done special dividends in the past, but there are no plans for one now."

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Netflix says plans to increase content spending across the board » 18:24
01/21/20
01/21
18:24
01/21/20
18:24
NFLX

Netflix

$338.24 /

-1.32 (-0.39%)

Says plans to increase…

Says plans to increase content spending across the board. Says content spending to grow roughly 20% in 2020. Says "The Crown" viewership has been very "durable" in the U.K., U.S. and across the world. Says losing rights to sitcom "Friends" has had no impact on viewership. Says "The Witcher" delivered viewing hours for the company, says viewers "loved it" right away.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Petrobras says CARF issued 'unfavorable' decision on tax proceeding » 18:23
01/21/20
01/21
18:23
01/21/20
18:23
PBR

Petrobras

$14.76 /

-0.41 (-2.70%)

Petrobras said that the…

Petrobras said that the Higher Chamber of the Administrative Tax Appeals Council issued today an unfavorable decision, by a casting vote, on an administrative tax proceeding which deals with the collection of PIS/COFINS - Import tax regarding remittances abroad for the payment of charters contracts in the calendar years of 2011 and 2012, in the approximate amount of R$9B. Petrobras is awaiting the summons of the decision and will take the judicial measures to defend its rights. The company understands that the decision does not change the possibility of loss expectation.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
First Midwest reports Q4 EPS 51c, consensus 50c » 18:15
01/21/20
01/21
18:15
01/21/20
18:15
FMBI

First Midwest

$21.58 /

-0.725 (-3.25%)

Reports Q4 revenue…

Reports Q4 revenue $194.9M, consensus $192.7M. Reports Q4 net interest margin 3.72% vs. 3.96% last year.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Netflix says Oscar-nominated original films 'very popular' with users as well » 18:14
01/21/20
01/21
18:14
01/21/20
18:14
NFLX

Netflix

$338.24 /

-1.32 (-0.39%)

, DIS

Disney

$143.53 /

-0.72 (-0.50%)

Netflix (NFLX) says…

Netflix (NFLX) says Disney+ (DIS) has "just one" big show, namely "The Mandalorian." Says has "big ticket" action films with movie stars coming later in the year, as well as popular young adult content coming in Q1 and Q2. Says has a "tremendous" film slate for this year. Says Oscar-nominated original films "very popular" with users as well. Says "Klaus" in Q4 was a "complete audience pleaser."

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Medtronic: Trial shows 'superior' back pain relief with DTM SCS » 18:12
01/21/20
01/21
18:12
01/21/20
18:12
MDT

Medtronic

$120.30 /

+1.32 (+1.11%)

Medtronic announced…

Medtronic announced three-month results from a large, multicenter randomized controlled trial showing statistically significant and superior back pain relief with Differential Target Multiplexed Spinal Cord Stimulation compared to conventional SCS. Both arms used the Medtronic Intellis platform. Three-month results showed 80% of patients with chronic back pain treated with DTM reported at least 50% pain relief, compared with 51% of patients treated with conventional SCS, as measured by the Visual Analog Scale, a widely used and accepted measure for pain intensity. 50% pain relief, as measured by VAS, is a recognized industry standard to define minimum therapy success. The RCT demonstrated profound pain relief and significant reductions in back and leg pain with DTM. 63% patients with back pain treated with DTM reported profound pain relief of 80% or greater compared to 26% treated with conventional SCS. In aggregate, patients treated with DTM reported an average of 74% reduction in back pain compared to 46% with conventional SCS at three months. Similarly, improvements were observed with DTM for leg pain with a mean reduction of 72% compared to 59% with conventional SCS. The RCT results reported are from 94 implanted SCS patients who were randomized to either the treatment or control arm and followed over the course of three months. With these results the study met its primary endpoint of noninferiority compared with conventional SCS, and a pre-specified secondary statistical test for superiority showing the difference between DTM and conventional SCS as highly significant. The study will continue to follow patients through 12 months post implant. Medtronic acquired DTM therapy as part of its acquisition of Stimgenics announced in early January. DTM therapy, which was proven through the RCT only on the Medtronic Intellis platform, is a new and unique programming option available to treat patients with chronic pain that is based on years of preclinical research.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Netflix says seasonality from Q1 to Q2 likely to be 'more balanced' » 18:07
01/21/20
01/21
18:07
01/21/20
18:07
NFLX

Netflix

$338.24 /

-1.32 (-0.39%)

, DIS

Disney

$143.53 /

-0.72 (-0.50%)

, GOOG

Alphabet

$1,484.92 /

+4.64 (+0.31%)

, GOOGL

Alphabet Class A

$1,482.70 /

+3.58 (+0.24%)

Netflix (NFLX) says Q1…

Netflix (NFLX) says Q1 2020 net additions guidance is still "big growth," though seems small compared to Q1 of 2019. Says seasonality from Q1 to Q2 likely to be "more balanced." Says long-term opportunity is "big" and "unchanged." Says Q4 net additions bodes well for growth going forward. Says competition from Disney+ (DIS) will largely draw viewers away from linear TV. Says competes a lot for time with YouTube (GOOG). Comments taken from Q4 earnings conference call.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.